← Leaderboards
Carl J Koschmann
University Of Michigan At Ann Arbor
$4,681,606
Attributed
$4,681,606
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,681,606 · 4
By mechanism
R01$3,659,691 · 2
K08$811,315 · 1
UH2$210,600 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Sami Nimer Malek$8,691,121
- Stefanie Galban$1,508,846
- Scott D Pletcher$23,572,111
- Dana Messinger$81,955
- Robert Pickett Dickson$8,802,133
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsMutationHistonesBindingGliomaGeneticPathway InteractionsBrain StemSiteChildhoodImpairmentH3 K27m MutationKnock-DownAtrx GeneNew Therapeutic TargetExperimental StudyBrainChildDna DamageCell Cycle ProgressionDna RepairEpigenetic ProcessGenetically Engineered MouseMouse Model
Grant awards (15)
Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma$426,151
R01 · FY2025 · NS · contact PI
The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma$390,000
R01 · FY2025 · NS · contact PI
Analytical and Clinical Validation of an H3K27M ctDNA Assay for Diffuse Midline Glioma (DMG) Surveillance$210,600
UH2 · FY2025 · CA · contact PI
Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma$459,296
R01 · FY2024 · NS · contact PI
The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma$378,300
R01 · FY2024 · NS · contact PI
Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma$396,063
R01 · FY2023 · NS · contact PI
The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma$390,000
R01 · FY2023 · NS · contact PI
Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma$439,881
R01 · FY2022 · NS · contact PI
The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma$390,000
R01 · FY2022 · NS · contact PI
The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma$390,000
R01 · FY2021 · NS · contact PI
Targeting ATRX-Deficient Pediatric GBM$158,263
K08 · FY2021 · NS · contact PI
Targeting ATRX-Deficient Pediatric GBM$163,263
K08 · FY2020 · NS · contact PI
Targeting ATRX-Deficient Pediatric GBM$163,263
K08 · FY2019 · NS · contact PI
Targeting ATRX-Deficient Pediatric GBM$163,263
K08 · FY2018 · NS · contact PI
Targeting ATRX-Deficient Pediatric GBM$163,263
K08 · FY2017 · NS · contact PI